KR20060096995A - 중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도 - Google Patents
중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도 Download PDFInfo
- Publication number
- KR20060096995A KR20060096995A KR1020067005458A KR20067005458A KR20060096995A KR 20060096995 A KR20060096995 A KR 20060096995A KR 1020067005458 A KR1020067005458 A KR 1020067005458A KR 20067005458 A KR20067005458 A KR 20067005458A KR 20060096995 A KR20060096995 A KR 20060096995A
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- oxo
- methyl
- trifluoromethyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302487-4 | 2003-09-18 | ||
| SE0302487A SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060096995A true KR20060096995A (ko) | 2006-09-13 |
Family
ID=29212489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067005458A Withdrawn KR20060096995A (ko) | 2003-09-18 | 2004-09-15 | 중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070043036A1 (enExample) |
| EP (1) | EP1663974B1 (enExample) |
| JP (1) | JP2007505902A (enExample) |
| KR (1) | KR20060096995A (enExample) |
| CN (1) | CN100439339C (enExample) |
| AR (1) | AR046083A1 (enExample) |
| AT (1) | ATE420861T1 (enExample) |
| AU (1) | AU2004272485B2 (enExample) |
| BR (1) | BRPI0414570A (enExample) |
| CA (1) | CA2538410A1 (enExample) |
| CO (1) | CO5670357A2 (enExample) |
| DE (1) | DE602004019110D1 (enExample) |
| ES (1) | ES2319300T3 (enExample) |
| IL (1) | IL173986A0 (enExample) |
| IS (1) | IS8394A (enExample) |
| MX (1) | MXPA06002723A (enExample) |
| NO (1) | NO20061700L (enExample) |
| RU (1) | RU2348617C2 (enExample) |
| SA (1) | SA04250300B1 (enExample) |
| SE (1) | SE0302487D0 (enExample) |
| TW (1) | TW200526579A (enExample) |
| UA (1) | UA84878C2 (enExample) |
| UY (1) | UY28513A1 (enExample) |
| WO (1) | WO2005026124A1 (enExample) |
| ZA (1) | ZA200602262B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| KR20080023680A (ko) | 2005-05-10 | 2008-03-14 | 인터뮨, 인크. | 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체 |
| EP2281813A1 (en) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| AU2006297036A1 (en) * | 2005-09-29 | 2007-04-05 | University Of Alberta | Compositions for and methods of granzyme B inhibition |
| GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| EP2077262A4 (en) | 2006-10-23 | 2011-12-28 | Takeda Pharmaceutical | IMINOPYRIDINE DERIVATIVE AND USE THEREOF |
| WO2008058229A1 (en) | 2006-11-08 | 2008-05-15 | Bristol-Myers Squibb Company | Pyridinone compounds |
| JP2011502982A (ja) | 2007-11-06 | 2011-01-27 | アストラゼネカ・アクチエボラーグ | 好中球エラスターゼの阻害剤としてのある種の２−ピラジノン誘導体およびその使用 |
| ATE502920T1 (de) | 2007-12-14 | 2011-04-15 | Pulmagen Therapeutics Asthma Ltd | Indole und ihre therapeutische verwendung |
| KR101596527B1 (ko) | 2008-01-23 | 2016-02-22 | 브리스톨-마이어스 스큅 컴퍼니 | ４-피리디논 화합물 및 암에 대한 그의 용도 |
| US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| GB0902648D0 (en) | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
| CN102395586A (zh) | 2009-02-17 | 2012-03-28 | 奇斯药制品公司 | 作为p38map激酶抑制剂的三唑并吡啶衍生物 |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| MX2012003644A (es) * | 2009-10-02 | 2012-04-30 | Astrazeneca Ab | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| CA2782384A1 (en) * | 2009-12-08 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| EP2740728A4 (en) | 2011-08-01 | 2015-04-01 | Sumitomo Dainippon Pharma Co Ltd | URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES |
| CA2858420A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract |
| JP6145849B2 (ja) | 2011-12-09 | 2017-06-14 | チエシ ファルマスーティシ エス．ピー．エー． | キナーゼ阻害剤 |
| PL2788349T3 (pl) | 2011-12-09 | 2017-04-28 | Chiesi Farmaceutici S.P.A. | Inhibitory kinaz |
| US20140057926A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140057920A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US9102624B2 (en) | 2012-08-23 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN105377847A (zh) | 2013-06-06 | 2016-03-02 | 奇斯药制品公司 | 激酶抑制剂 |
| US9221807B2 (en) * | 2014-02-21 | 2015-12-29 | Boehringer Ingelheim International Gmbh | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity |
| JP6525437B2 (ja) | 2014-04-02 | 2019-06-05 | インターミューン， インコーポレイテッド | 抗線維性ピリジノン |
| AU2016315360B2 (en) | 2015-09-02 | 2019-09-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| TW201730189A (zh) | 2015-12-23 | 2017-09-01 | 吉斯藥品公司 | 激酶抑制劑 |
| WO2017108736A1 (en) | 2015-12-23 | 2017-06-29 | Chiesi Farmaceutici S.P.A. | N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors |
| EP3394060A1 (en) | 2015-12-23 | 2018-10-31 | Chiesi Farmaceutici S.p.A. | 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors |
| JP7034942B2 (ja) | 2016-05-05 | 2022-03-14 | エフ．ホフマン－ラ ロシュ アーゲー | ピラゾール誘導体、その組成物及び治療的使用 |
| KR20190045302A (ko) | 2016-09-06 | 2019-05-02 | 에프. 호프만-라 로슈 아게 | 8-(아제티딘-1-일)-[1,2,4]트라이아졸로[1,5-a]피리딘일 화합물 및 이의 조성물 및 사용 방법 |
| JP6900491B2 (ja) | 2016-12-29 | 2021-07-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾロピリミジン化合物及びその使用方法 |
| EP3596072B1 (en) | 2017-03-14 | 2022-06-22 | F. Hoffmann-La Roche AG | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
| TW201902896A (zh) | 2017-05-22 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療化合物及組合物及其使用方法 |
| TW201900648A (zh) | 2017-05-22 | 2019-01-01 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及組成物以及其使用方法 |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| JP7339263B2 (ja) | 2018-01-15 | 2023-09-05 | エフ． ホフマン－ラ ロシュ アーゲー | Ｊａｋ阻害剤としてのピラゾロピリミジン化合物 |
| US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
| CN110192948B (zh) * | 2019-05-28 | 2022-01-04 | 河南省超亚医药器械有限公司 | 一种小儿腹部热敷贴 |
| CN110192947B (zh) * | 2019-05-28 | 2022-01-04 | 河南省超亚医药器械有限公司 | 一种小儿肺部热敷贴 |
| CN114008050B (zh) | 2019-06-18 | 2024-12-31 | 豪夫迈·罗氏有限公司 | Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途 |
| PH12021552998A1 (en) | 2019-06-18 | 2023-08-14 | Hoffmann La Roche | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
| JP7682110B2 (ja) | 2019-06-18 | 2025-05-23 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｊａｋキナーゼのテトラゾール置換ピラゾロピリミジン阻害剤及びその使用 |
| US20220354833A1 (en) | 2019-09-17 | 2022-11-10 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
| DK4106757T3 (da) | 2020-04-16 | 2023-10-23 | Mereo Biopharma 4 Ltd | Fremgangsmåder der involverer neutrofil elastase-inhibitor alvelestat til behandling af luftvejssygdom medieret af alpha-1-antitrypsin-mangel |
| CN118265527A (zh) | 2021-10-20 | 2024-06-28 | 美莱奥生物制药第四有限公司 | 用于治疗纤维化的中性粒细胞弹性蛋白酶抑制剂 |
| CN114057630B (zh) * | 2021-12-23 | 2023-06-02 | 郑州大学 | 吡非尼酮衍生物及其合成方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9207145D0 (en) * | 1991-04-18 | 1992-05-13 | Ici Plc | Heterocyclic amides |
| US5521179A (en) * | 1991-04-18 | 1996-05-28 | Zeneca Limited | Heterocyclic amides |
| FR2687674B1 (fr) * | 1992-02-07 | 1995-05-19 | Roussel Uclaf | Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
| ES2219457T3 (es) * | 1993-11-19 | 2004-12-01 | PARKE, DAVIS & COMPANY | Derivados de 5,6-dihidropironas como inhibidores de proteasa y agentes antiviricos. |
| RU2067579C1 (ru) * | 1994-10-07 | 1996-10-10 | Пермский фармацевтический институт | 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность |
| BR0116539A (pt) * | 2000-12-28 | 2003-09-23 | Shionogi & Co | Derivados de piridona tendo uma atividade de ligação para o receptor 2 do tipo canabinóide |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| DE60214428T2 (de) * | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-dihydro-1, 4-diphenylpyridin-derivate |
| GB2383326A (en) * | 2001-12-20 | 2003-06-25 | Bayer Ag | Antiinflammatory dihydropyridines |
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-09-18 SE SE0302487A patent/SE0302487D0/xx unknown
-
2004
- 2004-09-13 TW TW093127678A patent/TW200526579A/zh unknown
- 2004-09-15 DE DE602004019110T patent/DE602004019110D1/de not_active Expired - Fee Related
- 2004-09-15 CN CNB2004800275174A patent/CN100439339C/zh not_active Expired - Fee Related
- 2004-09-15 BR BRPI0414570-4A patent/BRPI0414570A/pt not_active IP Right Cessation
- 2004-09-15 KR KR1020067005458A patent/KR20060096995A/ko not_active Withdrawn
- 2004-09-15 WO PCT/SE2004/001336 patent/WO2005026124A1/en not_active Ceased
- 2004-09-15 JP JP2006526856A patent/JP2007505902A/ja active Pending
- 2004-09-15 US US10/572,640 patent/US20070043036A1/en not_active Abandoned
- 2004-09-15 CA CA002538410A patent/CA2538410A1/en not_active Abandoned
- 2004-09-15 MX MXPA06002723A patent/MXPA06002723A/es unknown
- 2004-09-15 AU AU2004272485A patent/AU2004272485B2/en not_active Ceased
- 2004-09-15 UY UY28513A patent/UY28513A1/es unknown
- 2004-09-15 ES ES04775439T patent/ES2319300T3/es not_active Expired - Lifetime
- 2004-09-15 UA UAA200602252A patent/UA84878C2/ru unknown
- 2004-09-15 EP EP04775439A patent/EP1663974B1/en not_active Expired - Lifetime
- 2004-09-15 RU RU2006112427/04A patent/RU2348617C2/ru not_active IP Right Cessation
- 2004-09-15 AT AT04775439T patent/ATE420861T1/de not_active IP Right Cessation
- 2004-09-17 AR ARP040103354A patent/AR046083A1/es not_active Application Discontinuation
- 2004-09-18 SA SA4250300A patent/SA04250300B1/ar unknown
-
2006
- 2006-02-27 IL IL173986A patent/IL173986A0/en unknown
- 2006-03-15 CO CO06026211A patent/CO5670357A2/es not_active Application Discontinuation
- 2006-03-17 ZA ZA200602262A patent/ZA200602262B/xx unknown
- 2006-03-31 IS IS8394A patent/IS8394A/is unknown
- 2006-04-18 NO NO20061700A patent/NO20061700L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5670357A2 (es) | 2006-08-31 |
| SA04250300B1 (ar) | 2008-09-07 |
| NO20061700L (no) | 2006-04-18 |
| HK1089167A1 (en) | 2006-11-24 |
| CN1856467A (zh) | 2006-11-01 |
| RU2006112427A (ru) | 2007-11-10 |
| CA2538410A1 (en) | 2005-03-24 |
| SE0302487D0 (sv) | 2003-09-18 |
| ZA200602262B (en) | 2007-07-25 |
| DE602004019110D1 (de) | 2009-03-05 |
| UA84878C2 (ru) | 2008-12-10 |
| AR046083A1 (es) | 2005-11-23 |
| ES2319300T3 (es) | 2009-05-06 |
| AU2004272485B2 (en) | 2008-03-13 |
| BRPI0414570A (pt) | 2006-11-07 |
| EP1663974A1 (en) | 2006-06-07 |
| ATE420861T1 (de) | 2009-01-15 |
| RU2348617C2 (ru) | 2009-03-10 |
| TW200526579A (en) | 2005-08-16 |
| JP2007505902A (ja) | 2007-03-15 |
| WO2005026124A1 (en) | 2005-03-24 |
| CN100439339C (zh) | 2008-12-03 |
| US20070043036A1 (en) | 2007-02-22 |
| EP1663974B1 (en) | 2009-01-14 |
| IS8394A (is) | 2006-03-31 |
| IL173986A0 (en) | 2006-07-05 |
| UY28513A1 (es) | 2005-04-29 |
| MXPA06002723A (es) | 2006-06-06 |
| AU2004272485A1 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060096995A (ko) | 중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도 | |
| KR101141464B1 (ko) | 중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도 | |
| EP1660460B1 (en) | Quinoxaline derivatives as neutrophil elastase inhibitors and their use | |
| JP2006513261A (ja) | 好中球エラスターゼの阻害剤としての２−ピリドン誘導体 | |
| CN100427469C (zh) | 作为嗜中性白细胞弹性蛋白酶抑制剂的喹啉衍生物及它们的用途 | |
| JP2008533136A (ja) | 好中球エラスターゼの阻害剤としての２−ピリジン誘導体 | |
| HK1089167B (en) | 2-pyridone derivatives as netrophil elastase inhibitors and their use | |
| HK1089166B (en) | 2-pyridone derivatives as neutrophil elastase inhibitors and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060317 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |